Biolargo, INC 8-K filings

BioLargo CEO Dennis Calvert provided a comprehensive business update during a shareholder town hall, highlighting progress in medical devices, environmental solutions, and advanced battery technology.

BioLargo, Inc. announced its CEO, Dennis P. Calvert, will participate in a shareholder town hall meeting on Discord on May 5, 2026, to provide a company update and answer questions.

BioLargo, Inc. has entered into a purchase agreement with ClearThink Capital Partners, LLC for up to $10 million in common stock over 36 months, enhancing its capital access.

BioLargo, Inc. announced its Annual Report for the year ended December 31, 2025, highlighting disciplined execution and commercialization advancements despite a significant revenue loss.

BioLargo, Inc. announced that two officers converted nearly $100,000 in unpaid salary and expenses into common stock, subject to a lock-up agreement.

BioLargo, Inc. will host an investor webcast on November 14, 2025, to present company updates.

BioLargo, Inc. announced its intent to present at the LD Micro Main Event XIX conference on October 20, 2025.

BioLargo, Inc. has revoked its exclusive license to Pooph Inc. and terminated their agreements due to Pooph's failure to pay approximately $3.8 million in royalties and product invoices, leading to a potential substantial asset impairment.

BioLargo, Inc. announced the presentation of a slide deck at a webcast investor conference held on August 15, 2025.

BioLargo, Inc. provided a mid-year review of its 2025 business highlights and future outlook, emphasizing the nearing commercialization inflection points for its diverse technology portfolio despite recent financial headwinds.

BioLargo, Inc. announced that all proposals at its 2025 annual stockholder meeting were approved, including granting the Board discretion for a reverse stock split, which is not immediately planned but reserved for a potential national exchange uplisting.

BioLargo, Inc. presented a slide deck at a webcast investor conference on May 15, 2025.

BioLargo announced record revenues for 2024, marking the tenth consecutive year of revenue growth, with a 45% increase over the previous year.

BioLargo reports an 80% year-to-date revenue increase, securing a record annual revenue with one quarter remaining in 2024.

BioLargo, Inc. presented a slide deck at a webcast investor conference on May 14, 2024, which is now being filed with the SEC.

BioLargo, Inc. successfully held its 2024 annual stockholder meeting, electing all director nominees and approving all proposals.

BioLargo, Inc. presented slides at its annual stockholder meeting on June 13, 2024, providing an update on the company's activities.

BioLargo reports positive operating cash flow of $481,000 and record quarterly revenues of $4.76 million for the first quarter of 2024.

BioLargo reports its annual revenues more than doubled for the second consecutive year, primarily driven by the success of its Pooph pet odor control product line.